$29.9M in CY2024 Part D spend5K claims · 1K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Abrocitinib used for?
Abrocitinib is a Janus Kinase Inhibitor medication tracked in Medicare Part D.
Is there a generic for Abrocitinib?
No. Abrocitinib is brand-only with no generic equivalents currently in market.
How much does my plan pay for Abrocitinib?
Across 329 Part D plans, Abrocitinib averages $197.20/unit (NADAC). Lowest available: $197.20/unit. Highest in distribution: $197.20/unit.
Is Abrocitinib on the FDA shortage list?
No. Abrocitinib is not currently on the FDA Drug Shortage Database.
7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (3 approvals on file) · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.